Discovery of Two Structurally Distinct Classes of Inhibitors Targeting the Nuclease MUS81 and Enhancing Efficacy of Chemotherapy in Cancer Cells

Nucleases are promising pharmacological targets due to their essential role in maintaining genomic stability. They are crucial for regulation of cell viability, and their modulation is exploitable in disease prevention and treatment, including cancer. The conserved structure-specific endonuclease MUS81 resolves branched DNA intermediates during replication, repair, and recombination. Aberrant MUS81 activity causes DNA damage, chromosomal abnormalities, and genome instability, contributing to oncogenesis. Thus, pharmacological targeting of MUS81 is an attractive yet underexplored therapeutic strategy. We describe the discovery of two chemically distinct small-molecule classes of MUS81 inhibitors, exemplified by compounds MU262 and MU876. Both compounds effectively inhibit MUS81 in vitro and in cells, sensitizing cancer cells to DNA-damaging agents by impairing DNA repair. These inhibitors can also serve as chemical biology tools for a deeper study of MUS81 function and as leads for drug discovery aimed at therapies exploiting DNA repair vulnerabilities in cancer treatment.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-02-25
DOI
https://doi.org/10.1021/acs.jmedchem.5c02096
Primary Topic
CRISPR and Genetic Engineering
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of Two Structurally Distinct Classes of Inhibitors Targeting the Nuclease MUS81 and Enhancing Efficacy of Chemotherapy in Cancer Cells

Petr Bartůněk, Jakub Cibulka, Fedor Nikulenkov, Claus M. Azzalin et al.
Journal of Medicinal Chemistry
CRISPR and Genetic Engineering
article

Discovery of Two Structurally Distinct Classes of Inhibitors Targeting the Nuclease MUS81 and Enhancing Efficacy of Chemotherapy in Cancer Cells

Petr Bartůněk, Jakub Cibulka, Fedor Nikulenkov, Claus M. Azzalin, Naresh Akavaram, Benoît Carbain, Victoria Marini, Lukáš Daniel, Kamil Paruch, Alexandra Sisáková, Prashant Khirsariya, Lumír Krejčí, Štěpán Havel, Magdalena Zacpalova, Jana Procházková, Michala Boudova, Magdalena Kalovska, Jan Brezovsky, Joana Rodrigues
article en

Abstract

Nucleases are promising pharmacological targets due to their essential role in maintaining genomic stability. They are crucial for regulation of cell viability, and their modulation is exploitable in disease prevention and treatment, including cancer. The conserved structure-specific endonuclease MUS81 resolves branched DNA intermediates during replication, repair, and recombination. Aberrant MUS81 activity causes DNA damage, chromosomal abnormalities, and genome instability, contributing to oncogenesis. Thus, pharmacological targeting of MUS81 is an attractive yet underexplored therapeutic strategy. We describe the discovery of two chemically distinct small-molecule classes of MUS81 inhibitors, exemplified by compounds MU262 and MU876. Both compounds effectively inhibit MUS81 in vitro and in cells, sensitizing cancer cells to DNA-damaging agents by impairing DNA repair. These inhibitors can also serve as chemical biology tools for a deeper study of MUS81 function and as leads for drug discovery aimed at therapies exploiting DNA repair vulnerabilities in cancer treatment.

Journal of Medicinal ChemistryVol. 69(5)
University of Debrecen (HU), University of Lisbon (PT), Masaryk University (CZ), Faculty (United Kingdom) (GB), National Clinical Research (US), Institute of Molecular Genetics (RU), Institute of Molecular Biology and Biotechnology (BG), St. Anne's University Hospital Brno (CZ), Institute for Molecular Medicine (US), Adam Mickiewicz University in Poznań (PL)
Good health and well-being
Openalex Percentile: Top 43%
CRISPR and Genetic Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.